Liraglutide API

Grade: Pharmaceutical Grade

Factory Location: Shanghai China

Main Sales Markets: North America,Central/South America,Western Europe,Eastern Europe,Australasia,Asia,Middle East,Africa

Monthly Production Capacity: 120KGS

Contract Manufacturing: CRO,CMO

Sample Provided: yes

Payment Terms: T/T

Liraglutide API (CAS No. 204656-20-2) is a glucagon-like peptide-1 (GLP-1) analog modified with a C-16 fatty acid side chain to prolong half-life. It comprises 31 amino acids and is produced via recombinant DNA technology using Saccharomyces cerevisiae (baker’s yeast).
Key Features:
• High Purity: Complies with pharmacopeial standards (CP/EP), ensuring minimal impurities.
• Bioactivity: Acts as a GLP-1 receptor agonist, enhancing glucose-dependent insulin secretion, suppressing glucagon, and delaying gastric emptying.
• Applications: Treats type 2 diabetes mellitus, obesity, and reduces cardiovascular risk in high-risk patients.

• Quality Assurance: Manufactured under cGMP; rigorously tested for identity, potency, sterility, endotoxins, and residual solvents.
Storage: Stable at 2–8°C; protect from light and freezing.